Palabra

Palabra is a biotechnology company focused on developing the next generation of programmable RNA medicines. Utilizing a proprietary circular RNA (circRNA) platform, the company aims to overcome the limitations of linear mRNA, such as stability and duration of expression. Palabra's technology is designed to enable long-lasting protein expression for a variety of therapeutic applications, including genetic diseases and oncology. The company is currently in the pre-clinical stage, building a pipeline of candidates based on its modular RNA architecture. Headquartered in San Francisco, Palabra was founded by experts in RNA biology and computational design to address the durability challenges of current nucleic acid therapies.